Isofol Medical

The information in the press release is intended for investors.

Today, Wednesday, March 12, at 1:30-1:55 p.m., Petter Segelman Lindqvist will present Isofol and the drug candidate arfolitixorin at Stora Aktiedagarna, arranged by Aktiespararna at Birger Jarl Conference in Stockholm. Arfolitixorin is being developed as a new treatment for severe forms of cancer and the company is currently preparing to initiate a clinical phase Ib/II study in metastatic colorectal cancer.

The presentations (in Swedish) will be live-streamed here:
https://invitepeople.com/events/db8431e8be

For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer 
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56

The information was submitted for publication, through the agency of the contact person set out above, at 07:45 CET, on March 12, 2025.

About Isofol Medical AB (publ)
Isofol Medical AB (publ) works to improve the prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is truly urgent. A phase Ib/II study is now being conducted with new dosage regimens that are expected to optimize the effect of the drug candidate.
Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofolmedical.com